Isabelle Mahé on Reduced Dose Apixaban for Cancer-Associated VTE: API-CAT Trial Results
Isabelle Mahé, Head of Internal Medicine, Louis Mourier Hospital, APHP, Paris Cité University, reposted from Syed Saad Mahmood on LinkedIn:
”Thank you very much for the opportunity to discuss the results of the API-CAT Study adressing the extended anticoagulant treatment in patients with cancer associated thrombosis!”
Syed Saad Mahmood, System Director, Cardio-Oncology at Catholic Health, shared on LinkedIn:
”*St Francis Heart Center, NY CardioOncology Journal Club*
Dr. Isabelle Mahe (Université Paris Cité, France) joined us to discuss *API-CAT trial* evaluating whether among active cancer patients with venous thromboembolism, tx with a reduced dose oral anticoagulant is effective in preventing recurrent thromboembolic events and reduced bleeding”
Find more from Cardio-Oncology Journal Club.
Watch the full episode here.
Stay updated on the latest advancements in hemostasis research with Hemostasis Today.
-
Feb 3, 2026, 10:53Aurelio Maggio: The Final Chapter of Our Journey Through Thalassemia
-
Feb 3, 2026, 10:40Pedro Perez: Post-Thrombectomy DVT Recovery in 2026 – Closing the Loop on Outcomes
-
Feb 3, 2026, 10:26Ryan Williams: This Article Brings to Light The Complexity of PRP…
-
Feb 3, 2026, 10:05Tiago Lopes: Can AI Predict Immune Reactions of New Drugs? Yes!
-
Feb 3, 2026, 09:51Rucha Patil Reflects on 49th MHG Annual Conference and Essence of ASH 2025
-
Feb 3, 2026, 09:37Grigoris Gerotziafas on VTE in MM and BCMA: We Are Pleased to Announce Our New Systematic Review
-
Feb 3, 2026, 09:24Early-Bird Registration for the WFH 2026 World Congress is Now Open
-
Feb 3, 2026, 09:15Joshua Bernstock: Prehospital Stroke Triage Has Hit a Ceiling
-
Feb 3, 2026, 09:00A Major Highlight of 2025 and Honour For Me: Ashkan Shoamanesh at Huashan International Stroke Conference